Join to View Full Profile
875 Blake Wilbur Dr"# Stanford"Stanford, CA 94304
Phone+1 650-723-7621
Fax+1 650-723-6661
Are you Dr. Mobasher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mehrdad Mobasher, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2007 - 2010
University of California (Irvine)Residency, Internal Medicine, 2004 - 2007
Tehran University of Medical Sciences School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2026
Publications & Presentations
PubMed
- 13 citationsVenetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint an...Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink
The Lancet. Haematology. 2022-03-01 - 16 citationsVenetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W. Flinn, Sam Yuen, Max S. Topp, Chiara Rusconi
Blood. 2020-12-03 - 3 citationsVenetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek
Haematologica. 2020-10-29
Press Mentions
BeiGene Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA® and Novel Pipeline AssetsDecember 9th, 2024- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLDecember 4th, 2024
- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLDecember 4th, 2024
- Join now to see all
